90 related articles for article (PubMed ID: 27830380)
21. Role of hepatic HCV-RNA level on the severity of chronic hepatitis C and response to antiviral therapy.
Maylin S; Laouénan C; Martinot-Peignoux M; Panhard X; Lapalus M; Nicolas-Chanoine MH; Bedossa P; Asselah T; Marcellin P
J Clin Virol; 2012 Jan; 53(1):43-7. PubMed ID: 22099210
[TBL] [Abstract][Full Text] [Related]
22. Hepcidin/ferroportin expression levels involve efficacy of pegylated-interferon plus ribavirin in hepatitis C virus-infected liver.
Kohjima M; Yoshimoto T; Enjoji M; Fukushima N; Fukuizumi K; Nakamura T; Kurokawa M; Fujimori N; Sasaki Y; Shimonaka Y; Murata Y; Koyama S; Kawabe K; Haraguchi K; Sumida Y; Harada N; Kato M; Kotoh K; Nakamuta M
World J Gastroenterol; 2015 Mar; 21(11):3291-9. PubMed ID: 25805936
[TBL] [Abstract][Full Text] [Related]
23. Adiponectin: a new independent predictor of liver steatosis and response to IFN-alpha treatment in chronic hepatitis C.
Zografos TA; Liaskos C; Rigopoulou EI; Togousidis E; Makaritsis K; Germenis A; Dalekos GN
Am J Gastroenterol; 2008 Mar; 103(3):605-14. PubMed ID: 18190648
[TBL] [Abstract][Full Text] [Related]
24. Chronic hepatitis C. Genotypes and response to anti-viral therapy among Saudi patients.
Al-Traif I; Handoo FA; Al-Jumah A; Al-Nasser M
Saudi Med J; 2004 Dec; 25(12):1935-8. PubMed ID: 15711670
[TBL] [Abstract][Full Text] [Related]
25. Effects of bezafibrate in patients with chronic hepatitis C virus infection: combination with interferon and ribavirin.
Fujita N; Kaito M; Kai M; Sugimoto R; Tanaka H; Horiike S; Konishi M; Iwasa M; Watanabe S; Adachi Y
J Viral Hepat; 2006 Jul; 13(7):441-8. PubMed ID: 16792537
[TBL] [Abstract][Full Text] [Related]
26. Boceprevir is highly effective in treatment-experienced hepatitis C virus-positive genotype-1 menopausal women.
Bernabucci V; Ciancio A; Petta S; Karampatou A; Turco L; Strona S; Critelli R; Todesca P; Cerami C; Sagnelli C; Rizzetto M; Cammà C; Villa E
World J Gastroenterol; 2014 Nov; 20(44):16726-33. PubMed ID: 25469044
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of pegylated interferon alfa-2a or alfa-2b in combination with ribavirin in the treatment of chronic hepatitis caused by hepatitis C virus genotype 1b.
Mach TH; Cieśla A; Warunek W; Janas-Skulina U; Cibor D; Owczarek D; Ciećko-Michalska I
Pol Arch Med Wewn; 2011 Dec; 121(12):434-9. PubMed ID: 22157768
[TBL] [Abstract][Full Text] [Related]
28. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
Martin-Carbonero L; Nuñez M; Mariño A; Alcocer F; Bonet L; García-Samaniego J; López-Serrano P; Cordero M; Portu J; Soriano V
AIDS; 2008 Jan; 22(1):15-21. PubMed ID: 18090387
[TBL] [Abstract][Full Text] [Related]
29. Viral decline over 48h and HCV amino acid mutations are related to efficacy of PEG-IFN/ribavirin.
Miyasaka A; Kumagai I; Abe K; Suzuki K
Hepatogastroenterology; 2012 May; 59(115):794-9. PubMed ID: 22020909
[TBL] [Abstract][Full Text] [Related]
30. Viral kinetic of HCV genotype-4 during pegylated interferon alpha 2a: ribavirin therapy.
Derbala MF; El Dweik NZ; Al Kaabi SR; Al-Marri AD; Pasic F; Bener AB; Shebl FM; Amer AM; Butt MT; Yakoob R; John A; Al Mohanadi M; Al Khinji MA
J Viral Hepat; 2008 Aug; 15(8):591-9. PubMed ID: 18482284
[TBL] [Abstract][Full Text] [Related]
31. Amino acid substitutions in hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by antiviral therapy.
Akuta N; Suzuki F; Hirakawa M; Kawamura Y; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H
J Med Virol; 2011 Jun; 83(6):1016-22. PubMed ID: 21503914
[TBL] [Abstract][Full Text] [Related]
32. Rapid virological response in peripheral blood mononuclear cells with an increase of hepatitis C virus-specific interferon-gamma production predisposes to sustained virological response in patients with chronic hepatitis C genotype 1 undergoing treatment with pegylated-interferon alpha 2a plus ribavirin.
Perrella A; Sbreglia C; Atripaldi L; Esposito C; D'Antonio A; Perrella O
Scand J Gastroenterol; 2010; 45(2):250-5. PubMed ID: 19968615
[TBL] [Abstract][Full Text] [Related]
33. Peginterferon alfa-2b plus weight-based ribavirin for 24 weeks in patients with chronic hepatitis C virus genotype 1 with low viral load who achieve rapid viral response.
Craxi A; Koutsounas S; Ogurtsov P; Chemello L; Maticic M; Torras J; Diago M; Tartaglione MT; Witthoeft T; Yu X; Faruqi R; Chaudhri E; Pedicone LD; Zuckerman E
J Viral Hepat; 2012 Feb; 19(2):e120-5. PubMed ID: 22239509
[TBL] [Abstract][Full Text] [Related]
34. Identification of novel defective HCV clones in liver transplant recipients with recurrent HCV infection.
Iwai A; Marusawa H; Takada Y; Egawa H; Ikeda K; Nabeshima M; Uemoto S; Chiba T
J Viral Hepat; 2006 Aug; 13(8):523-31. PubMed ID: 16901282
[TBL] [Abstract][Full Text] [Related]
35. Pioglitazone improves virological response to peginterferon alpha-2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance.
Khattab M; Emad M; Abdelaleem A; Eslam M; Atef R; Shaker Y; Hamdy L
Liver Int; 2010 Mar; 30(3):447-54. PubMed ID: 19919569
[TBL] [Abstract][Full Text] [Related]
36. [Dynamic changes in PD-1, TLR3, and TLR4 surface expression on peripheral blood mononuclear cells in chronic hepatitis C patients undergoing peg-IFNalpha-2a plus ribavirin combination therapy].
Zhang M; Jiang YF; Xiao XQ; Liu SF; Peng ML; Liu D; Gong GZ
Zhonghua Gan Zang Bing Za Zhi; 2013 Mar; 21(3):196-201. PubMed ID: 23967741
[TBL] [Abstract][Full Text] [Related]
37. Complete eradication of hepatitis C virus after interferon treatment for chronic hepatitis C.
De Mitri MS; Morsica G; Chen CH; Mele L; Baccarini P; Chianese R; Piccinini A; Lazzarin A; Pisi E
Ital J Gastroenterol Hepatol; 1997 Jun; 29(3):255-61. PubMed ID: 9646218
[TBL] [Abstract][Full Text] [Related]
38. The cost of treatment failure: resource use and costs incurred by hepatitis C virus genotype 1-infected patients who do or do not achieve sustained virological response to therapy.
Backx M; Lewszuk A; White JR; Cole J; Sreedharan A; van Sanden S; Diels J; Lawson A; Neal KR; Wiselka MJ; Ito T; Irving WL
J Viral Hepat; 2014 Mar; 21(3):208-15. PubMed ID: 24438682
[TBL] [Abstract][Full Text] [Related]
39. Optimal follow-up time to determine the sustained virological response in patients with chronic hepatitis C receiving pegylated-interferon and ribavirin.
Namikawa M; Kakizaki S; Yata Y; Yamazaki Y; Horiguchi N; Sato K; Takagi H; Mori M
J Gastroenterol Hepatol; 2012 Jan; 27(1):69-75. PubMed ID: 21649727
[TBL] [Abstract][Full Text] [Related]
40. Infection with the hepatitis C virus causes viral genotype-specific differences in cholesterol metabolism and hepatic steatosis.
Sheridan DA; Shawa IT; Thomas EL; Felmlee DJ; Bridge SH; Neely D; Cobbold JF; Holmes E; Bassendine MF; Taylor-Robinson SD
Sci Rep; 2022 Apr; 12(1):5562. PubMed ID: 35365728
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]